After a week of WHO granting the emergency Use Listing (EUL) to Bharat Biotech's Covaxin, The Lancet, a prestigious medical journal has said that Covaxin's phase 3 data demonstrates 77.8% efficacy against the COVID-19.

Check the tweet here:

(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)